Jagsonpal Pharmaceuticals Limited — Investor Meet, 27-04-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma delivered strong Q4FY26 results, with Revenue up 9.6% to ₹64.2 Cr and PAT up 31% to ₹8.8 Cr. For the full year FY26, Revenue grew 6.9% to ₹287.2 Cr, and PAT increased 19% to ₹44.6 Cr. The company’s cash position stands robust at ₹191 Cr. Management announced a ₹40 Cr share buyback at ₹250/share and a 200% dividend (totaling ₹26.2 Cr), highlighting disciplined capital allocation. The company outperformed industry growth (12.2% vs 8.6%), driven by sharper execution. Outlook indicates sustained acceleration through organic growth, new products, and inorganic avenues, targeting 1.5x IPM growth and improved margins. Management holds a confident view on future performance and shareholder value.